Mitotherapeutix, LLC is a biotechnology company that develops small interfering RNA (siRNA) based therapeutics targeting difficult disease pathways. The company focuses on modulating mitochondrial metabolic activity by inhibiting a negative gene regulator to treat a wide array of diseases.
Subscribe to see Mitotherapeutix, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mitotherapeutix, LLC is a biotechnology company headquartered in Woodbridge, United States. It has raised at least $3M across the 2 funding rounds on record. Its most recent funding round raised $3M in December 2017. Xcout tracks 11 named people at Mitotherapeutix, LLC, including Jack Talley (Chief Executive Officer/Manager).
As of 16 November 2026. Source: Xcout Intel.
5 more named people on record for Mitotherapeutix, LLC, with roles, board committees and tenure — see the full roster →
At least $3M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $3M | — | |
| SEC Form D filing | $30,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Mitotherapeutix, LLC's closest competitors — see the full list of competitors and alternatives →
MitoRx Therapeutics is a platform biotechnology company headquartered in Oxford, England, developing novel mitochondrial-targeted therapeutics for life sciences.
Sironax is a biopharmaceutical company committed to developing new treatments by targeting underlying contributors of degeneration, including neurodegenerative, inflammatory, and metabolic disorders.
MetasTx Inc. is a biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on creating novel therapeutics to treat diseases.
Paean Holdings, Inc. (operating as PAEAN Biotechnology) develops mitochondria-based therapeutics designed to treat rare diseases, inflammatory conditions, cancer, and central nervous system disorders. The company utilizes proprietary platforms including mitochondrial transplantation, modified mitochondria for targeted delivery, and mitochondria-augmented cell therapy to address critical medical needs and overcome cellular metabolic limitations.
Cellvie AG is a biotechnology company based in Zurich, Switzerland, pioneering Therapeutic Mitochondria Transplantation to target cellular energy metabolism.
Pretzel Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, advancing a new class of medicines that target cellular energetics and mitochondrial function.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Mitotherapeutix, LLC? Suggest a correction · Work at Mitotherapeutix, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.